New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT02734004
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study is testing a combination of two drugs, MEDI4736 (which helps the immune system fight cancer) and olaparib (which targets cancer cells with DNA repair problems), in people with advanced solid tumors like ovarian, breast, lung, and stomach cancers. The goal is to see if the combination can shrink or control the tumors. About 264 participants are involved, and the study is currently active but not recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Newnan, Georgia, 30265, United States
-
Research Site
Towson, Maryland, 21204, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Hilliard, Ohio, 43026, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Bordeaux, 33076, France
-
Research Site
Caen, 14076, France
-
Research Site
Clermont-Ferrand, 63011, France
-
Research Site
Dijon, 21079, France
-
Research Site
Marseille, 13385, France
-
Research Site
Nantes, 44202, France
-
Research Site
Paris, 75014, France
-
Research Site
Pierre Benit Cedex, 69495, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Haifa, 91096, Israel
-
Research Site
Jerusalem, 91031, Israel
-
Research Site
Petah Tikva, 49100, Israel
-
Research Site
Ramat Gan, 5265601, Israel
-
Research Site
Tel Aviv, 6423906, Israel
-
Research Site
Amsterdam, 1066 CX, Netherlands
-
Research Site
Amsterdam, 1081 HV, Netherlands
-
Research Site
Maastricht, 6229 HX, Netherlands
-
Research Site
Nijmegen, 6525 GA, Netherlands
-
Research Site
Rotterdam, 3075 EA, Netherlands
-
Research Site
Utrecht, 3584 CX, Netherlands
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 135-710, South Korea
-
Research Site
Chur, CH-7000, Switzerland
-
Research Site
Lausanne, 1011, Switzerland
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
Greater London, SW3 6JJ, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RY, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.